2 citations
,
April 2025 in “Cureus” Ki-67 levels do not predict treatment response in triple-negative breast cancer.
21 citations
,
December 2016 in “European journal of pharmaceutics and biopharmaceutics” Nano-sized lipid particles increase dexamethasone's skin penetration and create a reservoir in the skin layers.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
January 2005 in “Fuzhou daxue xuebao. Ziran kexue ban” The method is quick and effective for testing steroid 5 alpha-reductase inhibitors.
3 citations
,
April 1977 in “PubMed” The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
June 2026 in “Oriental Journal Of Chemistry” Steroid 12 shows promise as a targeted treatment for prostate cancer by selectively reducing cell growth and increasing cell death.
January 2026 in “International Journal of Women s Health” A new model helps predict treatment success in girls with early puberty.
March 2013 in “The Journal of Urology” Non-daily Dutasteride is more cost-effective and has lower cancer incidence than daily treatment.
18 citations
,
January 1990 in “Journal of The American Academy of Dermatology” Lower doses of dexamethasone can safely reduce high DHEAS levels in women with androgenic disorders.
7 citations
,
September 2017 in “Pharmacoepidemiology and Drug Safety” The use of Diane-35 and its generics significantly decreased in the Netherlands.
2 citations
,
August 2025 in “Scientific Reports” Pexidartinib often causes liver issues and fatigue, especially in women.
21 citations
,
August 1960 in “British journal of dermatology/British journal of dermatology, Supplement” Endoxan often causes hair loss, which usually starts in the third week of treatment.
1 citations
,
July 2021 in “Frontiers in Oncology” Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.
1 citations
,
September 2016 in “Acta Chromatographica” Created method to measure doxazosin mesylate and finasteride together.
June 2025 in “Experimental and Сlinical Urology” Predstanormix Duo is a safe and effective new drug for treating urinary symptoms from BPH.
26 citations
,
January 1992 in “Carcinogenesis” TPA strongly increases ODC activity in certain skin cells, potentially aiding tumor growth.
37 citations
,
December 2003 in “Reproductive Toxicology” The assay effectively detects hormonal activity of certain chemicals.
February 2026 in “Frontiers in Medicine” Personalized sonidegib dosing can effectively treat Gorlin-Goltz syndrome with fewer side effects.
110 citations
,
August 2015 in “Neuropsychopharmacology” High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
June 2026 in “Cancer Research Communications” The treatment combination is safe and effective for some patients with this type of breast cancer.
19 citations
,
July 2005 in “Steroids” Testosterone increases 3α-androstanediol levels, which can be blocked by finasteride.
2 citations
,
November 2022 in “Biosensors” A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.
5 citations
,
January 1995 in “Journal of Investigative Dermatology” A trial found that using finasteride, a hair growth drug, can be effectively measured by comparing before and after photos.
January 2004 in “Online Publication Service of Würzburg University (Würzburg University)” Women with PCOS have higher 5alpha-reductase activity, affecting steroid levels.
5 citations
,
September 2014 in “Journal of Pharmaceutical Sciences”
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
60 citations
,
August 2022 in “ESMO Open” Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.